|
|
 Previous Article | Table of Contents | Next Article 
An animal model of allogeneic donor platelet refractoriness: the effect of
the time of leukodepletion
MA Blajchman, L Bardossy, RA Carmen, M Goldman, NM Heddle and DP Singal
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Approximately 50% of multi-transfused individuals become refractory to
random donor platelets. Recent clinical data suggest that those patients
receiving leukocyte-depleted blood products are less likely to become
refractory to random donor platelets than recipients of non-
leukocyte-depleted products. Leukocyte depletion can be performed
immediately after collection of a unit of whole blood before its storage
(prestorage leukodepletion) or just before the transfusion of the blood
product to a recipient, after its storage (poststorage leukodepletion).
However, the most appropriate time for the leukodepletion of blood products
has not been established. The present study was undertaken to establish an
animal model of allogeneic platelet refractoriness, and to compare the
effect of prestorage and poststorage leukodepletion on the frequency of
refractoriness to allogeneic donor platelets. In this model, two strains of
rabbits were used: California Black rabbits were used as blood donors,
while New Zealand White rabbits were used as recipients. Eight weekly
infusions of nonleukodepleted allogeneic fresh blood resulted in an
allogeneic platelet refractory rate of 91.2% (31/34). The prestorage
leukodepletion of the donor blood was associated with a significantly
higher allogeneic platelet survival and lower refractory rate (33.3%) to
allogeneic platelets than poststorage leukodepletion (66.7%). Furthermore,
the data suggest that cell-free plasma products are capable of inducing
refractoriness to allogeneic donor platelets; the stored plasma having a
greater likelihood of inducing such refractoriness than fresh plasma. Thus,
these data provide evidence that the prestorage leukodepletion of
allogeneic donor blood is associated with a lower frequency of
refractoriness and better allogeneic platelet survival than poststorage
leukodepletion.
Volume 79,
Issue 5,
pp. 1371-1375,
03/01/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Fergusson, M. P. Khanna, A. Tinmouth, and P. C. Hebert
Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials: [La transfusion de sang reduit en leucocytes peut diminuer les infections postoperatoires : deux meta-analyses d'etudes randomisees et controlees]
Can J Anesth,
May 1, 2004;
51(5):
417 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Seftel, G. H. Growe, T. Petraszko, W. B. Benny, A. Le, C.-Y. Lee, J. J. Spinelli, H. J. Sutherland, P. Tsang, and D. E. Hogge
Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness
Blood,
January 1, 2004;
103(1):
333 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Sharma, G. Sreeram, T. Erb, H. P. Grocott, and T. F. Slaughter
Leukocyte-Reduced Blood Transfusions: Perioperative Indications, Adverse Effects, and Cost Analysis
Anesth. Analg.,
June 1, 2000;
90(6):
1315 - 1323.
[Full Text]
[PDF]
|
|
|
|
|
